Drug class profile · refreshed daily from federal data

Potassium-sparing Diuretic

3 molecules in this class, $9.6M combined CY2024 Part D spend across 184K claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 14 Jul 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Potassium-sparing Diuretic class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 3tracked in Part D
CY24 Part D spend: $9.6Mcombined across class
Total Rx claims: 184K56K unique beneficiaries
Generic mfrs (active): 4across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Triamterene

Brand: Dyrenium · 16K Part D claims (CY24) · 5K beneficiaries · First FDA approval: 1999-01-01

2 generic mfrs 0 plans require PA

Low NADAC$6.28

→

Avg plan cost$6.66

Part D spend $6.6M 1× spread, current vs floor

Class share

68%

of class CY24 spend

View profile →

Amiloride

169K Part D claims (CY24) · 51K beneficiaries · First FDA approval: 1986-01-22

2 generic mfrs 0 plans require PA

Low NADAC$0.200

→

Avg plan cost$0.200

Part D spend $3.1M 1× spread, current vs floor

Class share

32%

of class CY24 spend

View profile →

Triamterene Capsules

Brand: Triamterene · — Part D claims (CY24) · First FDA approval: 2018-12-12

Brand-only (no generics)

Low NADAC$6.28

→

Avg plan cost$6.66

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.